Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: Thorax. 2022 May 2;78(5):432–441. doi: 10.1136/thoraxjnl-2021-217674

Figure 1.

Figure 1

Derivation of the oral corticosteroid burst ICS response phenotype in GERA. 1Time period between the first and last ICS prescription dates; 2Subjects with days of OCS prescriptions ≥50% of ICS follow-up days were excluded, leaving subjects with OCS prescription coverage <50% of the ICS follow-up time; 3the following prespecified comorbidities were removed: cystic fibrosis, bronchiectasis, chronic obstructive pulmonary disease, pulmonary embolism, primary pulmonary hypertension; 4Subjects with identity-by-descent estimates >0.1875. GERA, Genetic Epidemiology Research on Adult and Aging; ICS, inhaled corticosteroid; OCS, oral corticosteroid.